The mammalian target of rapamycin (mTOR) is a key regulator of cell growth and its uncontrolled activation is a hallmark of cancer. Moreover,
Introduction
The mammalian target of rapamycin (mTOR) pathway is a central regulator of ribosome biogenesis and protein synthesis. Increasing evidence suggests that its exacerbated activation is associated with diseases involving deregulated growth, such as cancer, but also with metabolic diseases, such as type 2 diabetes and aging (Zoncu et al., 2011) . Epidemiologic data indicate that deregulation of the phosphatidylinositol 3-kinase (PI3K)/Akt/mTOR pathway, either via phosphatase and tensin homolog deleted on chromosome ten (PTEN) mutations or through Ras-mediated activation of PI3K, together with p53 are among the most prevalent alterations in human cancer (Hay and Sonenberg, 2004; Antonarakis et al., 2010) . In addition, the mTOR signaling pathway has been implicated in the resistance of cancer cells to many anticancer drugs such as vincristine, doxorubicin, retinoic acid, cisplatin, trastuzumab, and others (Hay and Sonenberg, 2004; Jiang and Liu, 2008) . Indeed, activated mTOR and elevated levels of its downstream targets, p70 ribosomal S6 kinase 1 (S6K1), eukaryotic translation initiation factor 4E (eIF4E), and its phosphorylated inhibitory binding protein, have been detected in high-grade human malignancies including prostate cancer (Antonarakis et al., 2010; Zoncu et al., 2011) . Moreover, activation of the mTOR pathway correlates with poor prognosis and reduced patient survival (Brown et al., 2008; Graff et al., 2009; Hollander et al., 2011) .
Therefore, mTOR has been considered as a promising target for the treatment of human malignancies (Hay and Sonenberg, 2004) , including chemoresistant, androgen-independent prostate cancer (Antonarakis et al., 2010) . To date, however, in clinical trials, the mTOR inhibitor rapamycin showed only limited success as an anticancer drug (Zoncu et al., 2011) . Activation of prosurvival and proliferative signals through Akt and extracellular signal-regulated kinase (ERK) cascades is held responsible for the cytostatic rather than cytotoxic effects of rapamycin and its analogs in the majority of human cancers (Efeyan and Sabatini, 2010) . The disappointing therapeutic efficacy motivated the search for new mTOR inhibitors with different mechanisms of action (Zoncu et al., 2011) . mTOR is a highly conserved Ser/Thr kinase belonging to the PI3K pathway activated by growth factors, nutrients, and stress. It serves as a catalytic subunit of two structurally and functionally distinct complexes, mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). In addition to mTOR, mTORC1 and mTORC2 contain RAPTOR and RICTOR, respectively. The two complexes signal via different effector pathways, thereby allowing control of distinct cellular processes. mTORC1 controls the translation machinery and regulates growth and metabolism via phosphorylation and activation of S6K1 and the inhibitory phosphorylation of the repressor of mRNA translation, 4E-binding protein 1, which in turn releases and activates eIF4E. eIF4E binds to the cap structure at the 59-end of mRNAs, and promotes recruitment of ribosome and the initiation of translation (Hay and Sonenberg, 2004; Zoncu et al., 2011) . Important functions of mTORC2 are actin organization and cell polarization. mTORC2 phosphorylates and activates the prosurvival kinase Akt as well as a number of other kinases supporting cell survival, cell-cycle progression, and anabolism (Hay and Sonenberg, 2004; Zoncu et al., 2011) .
Growth factors and increased ATP concentration positively regulate the mTORC1 activity (Hay and Sonenberg, 2004; Zoncu et al., 2011) . In addition, small ligands, such as amino acids and phosphatidic acid, elicit mTOR activation. Increased activity of phospholipase leading to enhanced production of phosphatidic acid in breast cancer cells is held responsible for the resistance of these cells to rapamycin (Chen et al., 2003) .
We recently identified distinct tetracyclic triterpenoids as potent Akt inhibitors (Estrada et al., 2010) . Furthermore, the pentacyclic triterpenoid acetyl-11-keto-b-boswellic acid (AKbBA) was found to induce apoptosis in vitro and in vivo in human prostate cancer (Syrovets et al., 2005b) , in colorectal cancer (Yadav et al., 2012) , and in human pancreatic tumor xenografts (Park et al., 2011) . AKbBA inhibits IkB kinase activity and subsequently nuclear factor-kB (NF-kB) both in vitro and in murine models in vivo (Syrovets et al., 2005a; Cuaz-Pérolin et al., 2008; Wang et al., 2009) . Cinnamic acid is a plant-derived organic acid frequently used in flavors because of its special scent; natural derivatives of cinnamic acid may also exhibit antitumor properties (De et al., 2011) . Here we introduce a novel esterified KbBA derivative, cinnamoyl-KbBA (C-KbBA), which inhibits mTOR and exhibits antiproliferative and proapoptotic activity on prostate cancer cells in vitro and in vivo in the chick embryo chorioallantoic membrane model.
Materials and Methods
Reagents. Calyculin A was from Santa Cruz Biotechnology (Santa Cruz, CA). Protease inhibitor cocktail III, Akt inhibitor VIII (1,3-dihydro-1-(1-((4-(6-phenyl-1H-imidazo[4,5-g] quinoxalin-7-yl) phenyl)methyl)-4-piperidinyl)-2H-benzimidazol-2-one, Akti-1/2), and compound C (6-[4-(2-piperidin-1-yl-ethoxy)-phenyl)]-3-pyridin-4-ylpyrrazolo[1,5-a]-pyrimidine, dorsomorphin, BMP inhibitor I) were from Calbiochem (San Diego, CA). CCI-779 (temsirolimus) was from LC Laboratories (Woburn, MA). Annexin V-fluorescein isothiocyanate and the terminal deoxynucleotidyl transferase-mediated digoxigenindeoxyuridine nick-end labeling kit were from Roche Diagnostics (Mannheim, Germany). Cinnamic acid, rapamycin, proteinase K, RNase A, propidium iodide, and phosphatidic acid were purchased from Sigma-Aldrich (St. Louis, MO). Protein phosphatase peptide substrate H-Arg-Arg-Ala-pThr-Val-Ala-OH (RRApTVA) was from Enzo Life Sciences (Farmingdale, NY). Antibodies against the following proteins were used: actin (Chemicon, Billerica, MA), eIF4E, S6K1, p-eIF4E Ser209 , topoisomerase I, cyclin D1 (all from Santa Cruz Biotechnology), Akt1, ERK1/2, IkB-a, p-IkBa, p-ERK1/2, p-p38, p-PDK Ser241 (Cell Signaling Technology, Danvers, MA), NF-kB p65, psignal transducer and activator of transcription 3 (p-STAT3), p-S6K1 (Epitomics, Burlingame, CA), Ki-67 (DAKO, Glostrup, Denmark), pAkt Ser473 (Upstate, Billerica, MA), and a-tubulin (Oncogene Research Products, La Jolla, CA). L-a-phosphatidic acid sodium salt from egg yolk, L-a-phosphatidylcholine type XVI-E, and lipopolysaccharide (Escherichia coli serotype 055:B5) were from Sigma-Aldrich. Human mTOR (also known as mechanistic target of rapamycin, mammalian target of rapamycin, FKBP12-rapamycin complex-associated protein, RAPT1, EC52.7.11.1) a.a. 1362-end, expressed in a baculovirusinfected Sf9 cell expression system, was from Biomol (Hamburg, Germany). High-performance liquid chromatography (HPLC) solvents and reagents were obtained from Merck (Darmstadt, Germany). African frankincense (i.e., oleogum resin from Boswellia carterii) was from Caesar & Lorentz GmbH (Hilden, Germany) (batch number 72598287).
Synthesis of C-KbBA from KbBA. AKbBA was isolated from the oleogum resin of African frankincense (B. carterii) and purified to chemical homogeneity (.99.5% purity) by reversed-phase HPLC (Belsner et al., 2003; Büchele and Simmet, 2003) . For the chemical characterization of the starting compound AKbBA, see the Supplemental Material. KbBA was generated from AKbBA by deacetylation. Derivatization of KbBA by Steglich esterification (Neises and Steglich, 1978) at position 3 of the ring A with cinnamic acid yielded C-KbBA, which was further purified by reversed-phase HPLC to chemical homogeneity (Fig. 1A) ; its structure was confirmed by mass spectrometry and one-and two-dimensional nuclear magnetic resonance spectroscopy (Supplemental Figs. 1 and 2 ) and compared with that of the parent compound, KbBA (Supplemental Fig. 3 ). The purity of the synthesized C-KbBA was more than 99.9% as analyzed by thin-layer chromatography, mass spectrometry, and HPLC (Supplemental Fig. 4 Fig. 5) .
Cell Lines. PC-3, LNCaP, DU-145 prostate cancer cells, RWPE-1 normal prostate cells, MDA-MB-231 breast cancer cells, and THP-1 monocytic leukemia cells were all from American Type Culture Collection (Manassas, VA). The PC-3 cell line overexpressing PTEN (PC-3-PTEN) (Zhao et al., 2004 ) was a generous gift from Dr. Derek LeRoith (Mount Sinai School of Medicine, New York, NY). The tuberous sclerosis complex (TSC2 2/2 and TSC2 1/1 ) mouse embryonic fibroblast cell lines (Zhang et al., 2007) were generous gifts from Dr. David J. Kwiatkowski (Brigham and Women's Hospital, Harvard Medical School, Boston, MA).
Cytotoxicity and Apoptosis Parameters. Cytotoxicity was quantified by the mitochondrial reduction of XTT (Roche Diagnostics) and by flow cytometric analyses of the phosphatidylserine expression on the outer membrane leaflet by binding of fluorescein isothiocyanatelabeled annexin V and of the subG 0 /G 1 peak of phosphatidylinositolstained cells. DNA fragmentation was analyzed by agarose gel electrophoresis (Estrada et al., 2010; Lunov et al., 2010) . For clonogenic cell survival, PC-3 (300 cells/cm 2 ) were treated with the compounds for 24 hours followed by 6 days in medium, and assayed spectrophotometrically after crystal violet staining. Caspase-3 activation was analyzed in cell lysates with a fluorogenic caspase substrate Z-DEVD-R110 (Molecular Probes, Eugene, OR).
Molecular Pharmacological Analyses. For Western blotting analysis, cells were starved in serum-free medium overnight, treated with compounds as indicated, and stimulated with 1% fetal calf serum for the indicated time. Nuclear extracts were isolated and Western immunoblotting was performed as described (Syrovets et al., 2005b) . Activation of forkhead box protein O1 (FOXO1) transcription factor was analyzed by TransAM (Active Motif, Carlsbad, CA). For the analysis of Ser/Thr protein phosphatase activity, PC-3 cells were pretreated with calyculin A (100 nM) for 20 minutes and then treated with C-KbBA for 30 minutes, followed by stimulation with 1% fetal calf serum for 1 hour. Clarified cell lysates were assayed spectrophotometrically using the phosphopeptide substrate RRApTVA. mTOR kinase assay was performed using recombinant S6K1-glutathione S-transferase and either the mTOR standard supplied in the K-LISA mTOR activity kit (Calbiochem) or mTOR precipitated with anti-mTOR/FKBP12-rapamycin complex-associated protein antibody (Calbiochem) from PC-3 cells (Syrovets et al., 2005b) . mTOR was pretreated with KbBA, C-KbBA, rapamycin, or wortmannin for 15 minutes before addition of the substrate for an additional 30 minutes. The phosphorylated S6K1 was resolved by gel electrophoresis and visualized by phosphorimaging (Syrovets et al., 2005b) . Akt1 kinase was assayed as described (Estrada et al., 2010) .
The cell cycle was analyzed in cells stained with propidium iodide in the presence of RNase A by flow cytometry using ModFit (BD Biosciences, San Jose, CA) (Syrovets et al., 2005b) .
The interaction of mTOR with phosphatidic acid was analyzed by photon correlation spectroscopy using a Zetasizer Nano ZS90 (Malvern, Worcestershire, UK) (Röcker et al., 2009; Hanlon et al., 2010) . Liposomes containing phosphatidic acid were prepared as described using a Liposo Fast lipid extruder (polycarbonate filters, 0.2 mm) from Avestin (Mannheim, Germany) (Guo et al., 2011) . The dissociation constant (K D ) of the mTOR/phosphatidic acid complex was calculated by fitting the experimental data to a mathematical binding model (Röcker et al., 2009 ).
Molecular Modeling. Computational docking and scoring studies of the ligand-protein interactions based on binding free energy (DG) were performed using Molegro Virtual Docker 5 ( Thomsen and Christensen, 2006; Estrada et al., 2010) . The nuclear magnetic resonance structure of the FKBP12-rapamycin-binding (FRB) domain of mTOR has been published (RCSB accession number 2GAQ) (Leone et al., 2006) . To confirm the specificity of the analysis, we have also performed molecular docking of C-KbBA with two other proteins, an mTORC1 downstream target, p70S6 kinase 1 (RCSB accession number 3A60) and protein phosphatase 2 (PP2A) (RCSB accession number 3DW8).
Tumor Xenografts. PC-3 cells (0. 7Â10 6 ) were seeded in medium/ Matrigel (1:1 v/v) (BD Biosciences) onto the chorioallantoic membrane of chicken eggs 6 days after fertilization. Starting 2 days after seeding, the cells were treated topically once daily for 4 days; tissue sections were finally analyzed immunohistochemically with an Axiophot microscope (Carl Zeiss, Göttingen, Germany) (Syrovets et al., 2005b) .
Statistical Analysis. Multiple group comparisons were conducted using the Newman-Keuls test (Statistica; StatSoft, Tulsa, OK).
Results

C-KbBA Is Cytotoxic for Prostate Cancer Cell Lines.
Searching for novel compounds with therapeutic efficacy against chemoresistant, androgen-independent prostate cancer, we have previously identified a series of plant-derived pentacyclic triterpenoids, which inhibit IkB kinase (IKK) that is essential for prosurvival signaling in many cancer cells (Syrovets et al., 2005a,b) . In addition, we classified several tetracyclic triterpenoids as inhibitors of Akt kinase (Estrada et al., 2010) . The presence of an acetyl group at position 3 of the ring A was consistently associated with an increased antiproliferative and antitumor activity of terpenoids. On the other hand, derivatives of cinnamic acid exhibit antitumor activity in various lymphomas, leukemias, and solid tumors IC 50 values were calculated using the Hill threeparameter mathematical model. All data are mean 6 S.E.M. n = 3. *P , 0.05. (De et al., 2011) . Therefore, we synthesized a number of pentacyclic triterpenoids on the basis of the terpenoid KbBA. Derivatization by Steglich esterification (Neises and Steglich, 1978) at position 3 of ring A of the parent compound, KbBA, with cinnamic acid led to C-KbBA (Supplemental Figs. 1-5 ).
C-KbBA induces time-and concentration-dependent inhibition of the PC-3 cell proliferation, with IC 50 s of about 4.2 and 3.6 mM after 24 and 48 hours of exposure, respectively (Fig. 1A) . By contrast, neither cinnamic acid nor its analog cinnamic acid methyl ester, which features better cell membrane permeability, elicited any significant cytotoxicity. C-KbBA was more potent than the structurally related triterpenoid AKbBA, which inhibits IKK. C-KbBA exhibited comparable cytotoxic efficacy also on other prostate cancer cell lines such as the androgen-dependent LNCaP and the androgen-independent DU-145 cells (Fig. 1B) . Compared with normal prostate epithelial cells, the toxicity of C-KbBA was preferentially directed against prostate cancer cells (Fig. 1C) .
C-KbBA Triggers Apoptosis in PC-3 Cells In Vitro. Treatment of PC-3 cells with C-KbBA triggered a concentrationdependent expression of phosphatidylserine on the outer membrane leaflet, an early sign of apoptosis (Fig. 2, A and B) , and induced a concentration-dependent caspase-3 activation (Fig. 2C) . Likewise, treatment of PC-3 cells with C-KbBA caused the typical DNA laddering pattern, a biochemical hallmark of irreversible apoptosis (Fig. 2D) .
C-KbBA Inhibits neither Akt nor NF-kB Signaling. Epidemiologic data indicate that sporadic mutation or deregulation of p53, PI3K, Akt, and PTEN are the most prevalent alterations in human cancer (Zoncu et al., 2011) . CKbBA is equally toxic for two prostate cell lines bearing p53 mutations (PC-3 and DU-145) and for LNCaP expressing wt p53 (Carroll et al., 1993) precluding the involvement of p53. PC-3 is a PTEN-null cell line. Loss of PTEN phosphatase, a negative regulator of Akt, results in constitutive activation of Akt, a phenomenon frequently observed in cancer (Hay and Sonenberg, 2004) and correlated with poor prognosis (Hollander et al., 2011) . We found that overexpression of active PTEN in PC-3 cells renders them less sensitive to CKbBA (Fig. 3A) suggesting that C-KbBA might target Akt or key downstream kinases such as IKK or mTOR.
Akt phosphorylates FOXO1, leading to its cytoplasmic retention and thereby rendering it transcriptionally inactive. Consistently, Akt inhibitor VIII significantly increased FOXO1 activation. However, C-KbBA had no such effect (Fig. 3B) . Similarly, C-KbBA did not affect phosphorylation of Akt, neither on Ser473 nor on Thr308, both of which are indispensable for Akt kinase activation. Moreover, C-KbBA did not inhibit phosphorylation of the major Akt substrate, glycogen synthase kinase 3b (GSK-3b) (Fig. 3D ). C-KbBA had also no effect on the constitutively active 3-phosphoinositidedependent protein kinase 1 (PDK1), a kinase upstream of Akt, and did not influence the activity of ERK1/2 (Fig. 3, C and D) . Likewise, C-KbBA does not inhibit phosphorylation and activation of the mitogen-activated protein kinase ERK1/2 and p38, or NF-kB and STAT3 in monocytic leukemia cells ( Supplemental Fig. 6 ); those cells were chosen because they respond with all of the aforementioned signaling pathways to the standard stimulus lipopolysaccharide. These data indicate that although an intact Akt signaling pathway is indispensable for the anticancer activity of C-KbBA, this compound has no direct inhibitory effect on Akt, PDK1, or ERK1/2. Interestingly, at variance to C-KbBA, CCI-779 and rapamycin caused a marked increase in phosphorylation of GSK-3b, the downstream target of Akt (Fig. 3D) . This is believed to be a consequence of a concomitant activation of mTORC2 known to induce Akt activation when mTORC1 is inhibited by rapamycin or rapamycin analogs (Zoncu et al., 2011) .
We previously showed that the acetylated form of KbBA, AKbBA, induces apoptosis by downregulation of the NF-kB signaling pathway (Syrovets et al., 2005b) . However, C-KbBA did not affect NF-kB (Fig. 3E) . Akin to C-KbBA, the rapamycin analog CCI-779 is a less potent inhibitor of the proliferation of PC-3-PTEN cells exhibiting low Akt activity (Fig. 3F) . These data suggest that C-KbBA might target mTOR.
C-KbBA Inhibits the mTOR Signaling Pathway In Vitro and In Vivo. Within 30 minutes, hence far ahead of any detectable cytotoxicity, C-KbBA induced a concentrationdependent downregulation of the phosphorylation of S6K1 kinase in PC-3 cells (Fig. 4A ) and enhanced the phosphorylation of eIF4E, although to a lesser extent than CCI-779 or rapamycin (Fig. 4B) . The phosphorylation of eIF4E was, however, absent in DU-145 prostate cancer cells treated with C-KbBA (Supplemental Fig. 6 ). These cells differ from PC-3 by having a low basal Akt/mTOR activity due to PTEN expression. C-KbBA, CCI-779, and rapamycin also inhibited the expression of eIF4E (Fig. 4B) , which might reduce the capdependent translation of preferentially protumorigenic genes (D) C-KbBA (5 mM) induces DNA laddering (96 h). All data are mean 6 S.E.M. n = 3. *P , 0.05; **P , 0.01. (Graff et al., 2009) , including cell-cycle regulators such as cyclin D1 (Zoncu et al., 2011) as shown in Fig. 4B .
The proto-oncogene cyclin D1 is a key regulator of the transition from the G 1 to the S phase (Alao et al., 2006) . Consistently, treatment of PC-3 cells with C-KbBA elicited arrest in the G 1 phase of the cell cycle (Fig. 4, C and D) . Notably, a single treatment with C-KbBA for 24 h inhibited the clonogenic survival of PC-3 cells grown for the next 6 days in medium without the inhibitor (Fig. 4, E and F) .
Next, C-KbBA concentration-dependently inhibited proliferation of PC-3 prostate cancers grafted on chick chorioallantoic membranes as assessed by immunohistochemical analysis of proliferation marker Ki-67 and impeded phosphorylation of the mTOR substrate S6K1, thereby confirming inhibition of mTOR signaling in vivo. Concomitantly, CKbBA, but not rapamycin, increased the rate of apoptosis in the tumor xenografts (Fig. 4, G and H) .
C-KbBA Inhibits the mTOR Signaling Pathway Independently of the Liver Kinase B1-AMP-Activated Protein Kinase, TSC Complex, and Protein Phosphatases. The AMP-activated protein kinase (AMPK)-TSC network is a negative upstream regulator of mTORC1. In response to low energy level or high AMP level, AMPK is activated by phosphorylation by liver kinase B1 (LKB1) leading to phosphorylation of TSC2 and activation of the TSC complex and inhibition of the mTORC1 signaling (Zoncu et al., 2011) . As expected, inhibition of AMPK by compound C enhanced the mTORC1-induced phosphorylation of S6K1. However, inhibition of AMPK did not revert the inhibitory effect of C-KbBA on the mTORC1-induced phosphorylation of S6K1 (Fig. 5A) . Moreover, C-KbBA proved to be cytotoxic to MDA-MB-231 cells, which do not express LKB1 (Shen et al., 2002) (Fig. 5B) . Thus, C-KbBA inhibits mTOR independently of AMPK and LKB1 signaling.
Ser/Thr protein phosphatases such as PP2A are essential components of mTOR signaling in mammalian cells, where they control the activity of the mTORC1 substrates (Rohde et al., 2001 ). The activity of the Ser/Thr protein phosphatases ) were treated as in (A) for 24 hours. After recovering for 6 days in medium free of compounds, cell survival was assayed spectrophotometrically. (G and H) C-KbBA inhibits proliferation of PC-3 tumor xenografts on the chick chorioallantoic membrane. PC-3 cells were grafted onto the chorioallantoic membrane of fertilized chicken eggs. After 2 days, the tumors were treated with C-KbBA, rapamycin, or in cells treated with C-KbBA remained, however, unaffected compared with the phosphatase inhibitor calyculin A-treated cells (Fig. 5C) .
In addition to Akt and AMPK, the TSC2 subunit can be phosphorylated by ERK1/2, and ribosomal S6 kinase 1, a kinase downstream of ERK. Inhibition of any of these kinases would also result in the inhibition of mTORC1 signaling (Bai and Jiang, 2010) . C-KbBA did not inhibit the phosphorylation and activation of Akt, whereas the ERK kinases were not activated in the prostate cancer cells (Fig. 3, B-D) . However, C-KbBA might target the TSC complex directly, thereby inhibiting mTOR signaling. Two mouse embryonic fibroblast cell lines, one expressing TSC2 and the other one not, were treated with C-KbBA. C-KbBA is equally cytotoxic to either cell line, suggesting independence from the expression of TSC2 (Fig. 5D) .
These data suggest that C-KbBA might target mTOR directly. However, the mechanism of C-KbBA seems to differ from that of rapamycin and CCI-779, which are cytostatic rather than cytotoxic (Fig. 5E) . Indeed, comparison of KbBA, C-KbBA, CCI-779, and rapamycin revealed that in terms of the subG 0 /G 1 peak, C-KbBA is a much better inducer of apoptosis than rapamycin, the rapamycin analog, or the parent compound KbBA (Fig. 5F) .
Evidence for Competition of C-KbBA with Phosphatidic Acid Binding to the FRB Domain of mTOR. The activity of mTOR is modulated by a number of small ligands including phosphatidic acid and rapamycin, both of which bind to the FRB domain of mTOR pointing to a special role of this domain in controlling the catalytic activity of mTOR (Veverka et al., 2008; Yoon et al., 2011; Zoncu et al., 2011) . In silico molecular docking did not reveal any significant binding affinity of C-KbBA to S6K1 or PP2A. In contrast, it predicted high affinity binding of C-KbBA to the FRB domain of mTOR (Fig. 6, A and B ) with low energy interaction indicative for a stable binding system (Thomsen and Christensen, 2006) . Recently, binding of phosphatidic acid has been characterized by nuclear magnetic resonance (Veverka et al., 2008; Yoon et al., 2011) . Our molecular modeling approach confirmed the earlier identified binding mode of phosphatidic acid and indicated that C-KbBA could interact with the same amino acid residues of mTOR that are involved in the interaction with phosphatidic acid but with higher affinity. The calculated K D of C-KbBA binding to the FRB domain in mTOR (Fig. 6C) correlated well with the inhibitory values obtained in cell-based assays (Fig. 1) and was superior to the structurally related KbBA and AKbBA. Consistent with the biochemical data, the calculated binding efficacy of C-KbBA for Akt1, ERK2, IKKa, and IKKb was negligible (Supplemental Table 1 ).
Phosphatidic acid is produced by hydrolysis of phosphatidylcholine by phospholipase D. Cells that exhibit high phospholipase D activity and high levels of phosphatidic acid solvent (control) for 4 days. The tumor sections were stained against Ki-67 (proliferation marker, dark violet), terminal deoxynucleotidyl transferase-mediated digoxigenin-deoxyuridine nick-end labeling (TdT, apoptosis marker, dark brown), and p-S6K1 (pink) (G). Quantification of the proliferating cells in tumors (H). Where applicable, data are mean 6 S.E.M. n = 3. **P , 0.01. ) was measured by the XTT assay after exposure for 48 hours. (E) C-KbBA is cytotoxic to PC-3 cells, which are resistant to rapamycin and the rapamycin analog CCI-779. Cell viability was measured by XTT assay (24 hours). (F) C-KbBA is cytotoxic to PC-3 cells, which are resistant to rapamycin and the rapamycin analog CCI-779. are highly resistant to rapamycin, such as MDA-MB-231 breast cancer cells (Chen et al., 2003) . However, C-KbBA is cytotoxic to MDA-MB-231 cells, indicating that it successfully competes with phosphatidic acid for binding to mTOR within the cells (Fig. 5B) . Addition of phosphatidic acid to prostate cancer cells increased the mTOR activity and S6K1 phosphorylation as expected. However, C-KbBA effectively inhibited the phosphatidic acid-induced mTOR activation (Fig.  6D) . Moreover, in the presence of C-KbBA, the affinity of mTOR to phosphatidic acid decreased almost 10-fold (Fig.  6E) . Detailed analysis of the specific binding showed a parallel shift of the binding curve to the right indicative for a competitive mode of inhibition (Supplemental Fig. 7) . These data are in agreement with our molecular modeling showing higher affinity of mTOR for C-KbBA than for phosphatidic acid. Finally, a kinase assay using either commercial active mTOR or mTOR immunoprecipitated from PC-3 cells and devoid of FKB12 demonstrated that C-KbBA indeed inhibited mTOR activity and the S6K1 phosphorylation, whereas rapamycin was inactive in the absence of FKBP12 cofactor protein (Fig. 6F) .
Discussion
Due to the crucial role of mTOR signaling for the proliferation of malignant cells and the fact that even full inhibition of mTORC1 and mTORC2 could be well tolerated in adult tissues (Zoncu et al., 2011) , mTOR inhibitors have been tested in a number of clinical trials. The immunosuppressive macrolide rapamycin is considered the classic mTOR inhibitor. Since rapamycin and its derivatives CCI-779 (temsirolimus) and RAD-001 (everolimus) exhibited potent antiproliferative activity against various cancer cell lines and favorable toxicity profiles, they have been clinically explored in several trials for the treatment of neoplastic diseases (Antonarakis et al., 2010) . Indeed, CCI-779 and RAD-001 are currently approved for the treatment of advanced metastatic renal cell carcinoma. AP23573 (deforolimus) is presently being evaluated in clinical studies against docetaxel-refractory, advanced, castration-resistant prostate cancer. It is, however, expected that classic mTOR inhibitors such as rapamycin and its analogs will have little effect as single agents, and are likely to be more promising in combination therapy with other chemotherapeutics, where they increase cancer cell sensitivity to these drugs (Antonarakis et al., 2010) .
To achieve an effective mTOR-based cancer therapy, some limitations of the rapamycin therapy have to be overcome. The most important one is a severe upregulation of MEK-ERK and PI3K/Akt signaling due to the S6K1-mediated feedback loop and TORC2-mediated activation of Akt. These mechanisms upregulate important prosurvival and proliferative signals, which dampen the inhibitory effects of rapamycin in preclinical models and in cancer patients (Efeyan and Sabatini, 2010; Zoncu et al., 2011) . Activation of these antiapoptotic feedback loops might also explain why rapamycin and its analogs emerge as cytostatic rather than cytotoxic drugs (Efeyan and Sabatini, 2010; Zoncu et al., 2011) . On this background, development of catalytic inhibitors of mTOR with mechanisms of action different from that of rapamycin may prove especially useful (Zoncu et al., 2011) .
The mechanism of action of C-KbBA identified in this study differs from that of rapamycin and its analogs. Notably, CKbBA does not induce a feedback activation of Akt observed as hyperphosphorylation of GSK-3b, when cells had been treated with rapamycin or CCI-779. However, similar to rapamycin and CCI-779, C-KbBA induces a modest increase in phosphorylation of eIF4E. The physiologic consequences of eIF4E phosphorylation are not well established. Thus, fluorescence spectroscopy and surface plasmon resonance analyses demonstrated that phosphorylation of eIF4E markedly reduces its affinity for capped RNA, primarily due to an increased rate of dissociation (Scheper et al., 2002) . In other studies, the oncogenic activity of eIF4E correlates with its phosphorylation on Ser209 (Bianchini et al., 2008; Furic et al., 2010) . elF4E phosphorylation may result from residual mTORC2 activity, known to induce phosphorylation of eIF4E via MNK . Although C-KbBA upregulates the eIF4E phosphorylation, it markedly reduces the eIF4E expression in prostate cancer cells. In this regard, the overall expression levels of eIF4E might be a better indicator of the prostate cancer malignancy. The elevated levels of eIF4E are associated with prostate cancer progression (Kremer et al., 2006) , and its reduction in prostate cancer cells elicits apoptosis (Graff et al., 2009) . Accordingly, eIF4E is hardly expressed in normal prostate tissues, whereas in prostate cancer, it is highly expressed and phosphorylated (Graff et al., 2009 ). Cyclin D1 is considered the prime downstream target protein of eIF4E-mediated protein translation, and expression of eIF4E significantly correlates with the level of cyclin D1 protein expression because eIF4E enhances the nuclear export of cyclin D1 mRNA (Hay and Sonenberg, 2004) . Cyclin D1, on the other hand, is a key regulator of the G 1 phase of the cell cycle, and drives cells through the G 1 /S phase transition (Stacey, 2003) . Indeed, we found that CKbBA reduced the expression of cyclin D1 and arrested cells in the G 1 phase.
To elucidate the molecular mechanisms of C-KbBA, we used different approaches. LKB1 phosphorylates and activates TSC2 of the TSC complex leading to the inhibition of mTORC1. An effect of C-KbetaBA on the TSC2 signaling network was, however, ruled out because C-KbBA was cytotoxic to MDA-MB-231, a cell line, which does not express LKB1 (Shen et al., 2002) , and for TSC 2/2 mouse embryonic fibroblasts. These data implicated that C-KbBA affects mTOR directly. A number of new catalytic inhibitors of mTORC1 and mTORC2 competing with binding of ATP have been synthesized. Such catalytic inhibitors of mTOR are well tolerated in the clinical setting in adults (Zoncu et al., 2011) . However, under conditions of prolonged treatment with catalytic mTOR hydrodynamic radii of mTOR/phosphatidic acid complexes (Dr) was measured by photon correlation spectroscopy. mTOR (1-300 pM) preincubated for 15 minutes with 10 mM C-KbBA or vehicle, was mixed with phosphatidic acid-containing liposomes for 15 minutes, and analyzed. (F) C-KbBA inhibits the mTORC1 activity in an in vitro kinase assay. The mTOR standard (20 ml) or immunoprecipitated mTOR in the absence of FKBP12 were pretreated for 15 minutes with KbBA (10 mM), C-KbBA, wortmannin (each 10 mM), or rapamycin (10 nM) prior to addition of recombinant S6K1 for 30 minutes. Phosphorylated substrate was visualized by phosphor imaging. (G) Scheme of the mTORC1 signaling pathway.
inhibitors, mTOR-independent activation of Akt was observed, which led to activation of some Akt substrates, such as FOXO1 (Zoncu et al., 2011) . In contrast, a single treatment with C-KbBA effectively inhibited the clonogenic growth of prostate cells, in the absence of FOXO1 activation in CKbBA-treated cells. Hence, the compound shows a greatly improved pharmacodynamic profile.
The lipid second messenger phosphatidic acid along with amino acids is a strong activator of mTOR. It is required for the association of mTOR with Raptor within mTORC1 and that of mTOR with Rictor within mTORC2 (Toschi et al., 2009) . It displaces FKBP38 from mTOR and, in addition, allosterically stimulates the catalytic activity of mTORC1 (Veverka et al., 2008; Yoon et al., 2011) . C-KbBA, which competes with phosphatidic acid for binding to mTOR, might interfere with this dual activation, which results in inhibition of the mTORC1 catalytic activity. We did not observe inhibition of mTORC2-mediated activation of Akt by C-KbBA. On the other hand, whereas GSK-3b was hyperphosphorylated in rapamycin-and CCI-779-treated cells, C-KbBAtreated cells apparently did not exhibit activated Akt signaling. This might be a result of partial inhibition of the mTORC2 complex by C-KbBA, or of direct inhibitory effects on Akt. The latter is, however, less probable, because the concentrations of C-KbBA used did not detectably affect Akt. Thus, effects of C-KbBA on mTORC2 cannot be excluded. In fact, this might be an advantage of the compound, because mTORC2, although neglected for some time, appears to be of special importance for tumorigenesis under conditions of PTEN deficiency (Guertin et al., 2009) , particularly in metastatic prostate cancer (Antonarakis et al., 2010) .
Taken together, the novel semisynthetic terpenoid C-KbBA inhibits cell proliferation and induces apoptosis in vitro and in vivo in the chick embryo chorioallantoic membrane model even at low concentrations and after a single, rather short exposure. These effects of C-KbBA are triggered by its inhibition of the mTOR signaling pathway that occurs independent from the upstream kinases Akt and PDK1, and independent from the negative regulators of mTOR signaling, TSC2 and PP2A. C-KbBA exhibits a preferential efficacy against prostate cancer cells (i.e., the PC-3 cell line harboring defects in the apoptosis pathway) compared with normal prostate epithelial cells.
The capability of C-KbBA to inhibit the mTOR signaling pathway renders it an interesting lead compound for the development of novel pharmacotherapeutic approaches for the treatment of cancer and as a tool for dissecting signaling pathways on the molecular level.
